• Pharmacology
  • Allergy, Immunology, and ENT
  • Cardiology
  • Emergency Medicine
  • Endocrinology
  • Adolescent Medicine
  • Gastroenterology
  • Infectious Diseases
  • Neurology
  • OB/GYN
  • Practice Improvement
  • Gynecology
  • Respiratory
  • Dermatology
  • Mental, Behavioral and Development Health
  • Oncology
  • Rheumatology
  • Sexual Health
  • Pain

FDA approves first once-daily drug for ADHD

Article

The US Food and Drug Administration (FDA) has approved extended-release methylphenidate hydrochloride oral suspension for the treatment of attention-deficit/hyperactivity disorder (ADHD). Efficacy was determined in a randomized, double-blind, crossover study that showed improvement for both attention and behavior metrics for up to 12 hours in children aged 6 to 12 years diagnosed with ADHD compared with placebo. The once-daily treatment will be available in January 2013.

The US Food and Drug Administration (FDA) has approved extended-release methylphenidate hydrochloride oral suspension for the treatment of attention-deficit/hyperactivity disorder (ADHD). Efficacy was determined in a randomized, double-blind, crossover study that showed improvement for both attention and behavior metrics for up to 12 hours in children aged 6 to 12 years diagnosed with ADHD compared with placebo. The once-daily treatment will be available in January 2013.

Related Videos
Donna Hallas, PhD, CPNP, PPCNP-BC, PMHS, FAANP, FAAN
Image credit: Kyle Dykes
J. Thomas Megerian, MD, PhD, FAAP | Author provided
Colleen Kraft, MD | Image Credit: Children's Hospital Los Angeles
Image Credit: Contemporary Pediatrics®
Related Content
© 2024 MJH Life Sciences

All rights reserved.